Gustavo Lopez, MD
Family Medicine · Tolleson, AZNPI 1023247202
Payments from drug & device makers
Across 130 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$502
- Boehringer Ingelheim$275
- Johnson & Johnson$228
- Novo Nordisk$221
- AbbVie$155
- Merck$149
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,656100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $502 |
| Boehringer Ingelheim | 13 | $275 |
| Johnson & Johnson | 11 | $228 |
| Novo Nordisk | 12 | $221 |
| AbbVie(2 entities) | 8 | $155 |
| Merck | 10 | $149 |
| Boston Scientific | 5 | $136 |
| Lilly USA, LLC | 12 | $121 |
| AstraZeneca | 7 | $88 |
| Bayer | 5 | $75 |
| Astellas Pharma US Inc | 2 | $63 |
| Pfizer | 1 | $59 |
| Scilex Pharmaceuticals Inc. | 1 | $48 |
| Dexcom, Inc. | 2 | $48 |
| Corcept Therapeutics | 3 | $48 |
| GSK | 3 | $47 |
| Redhill Biopharma Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 3 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| IBSA Pharma Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Novartis | 2 | $28 |
| Eisai Inc. | 2 | $25 |
| Abiomed | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Exact Sciences | 1 | $15 |
| Sonex Health, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUADRA ASSURA$175
- Assurity Pacemaker$117
- INVOKANA$109
- JARDIANCE$107
How this compares
$2,661 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 189 | $284,141 |
| JanuviaSitagliptin Phosphate | 107 | $149,772 |
| TradjentaLinagliptin | 114 | $129,937 |
| GlyxambiEmpagliflozin/Linagliptin | 74 | $106,172 |
| EliquisApixaban | 71 | $92,159 |
| FarxigaDapagliflozin Propanediol | 60 | $74,242 |
| TrulicityDulaglutide | 47 | $63,900 |
| LinzessLinaclotide | 64 | $61,158 |
| KerendiaFinerenone | 39 | $57,577 |
| MounjaroTirzepatide | 37 | $42,897 |
| JanumetSitagliptin Phos/Metformin Hcl | 35 | $36,728 |
| EntrestoSacubitril/Valsartan | 18 | $32,089 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $31,026 |
| OzempicSemaglutide | 28 | $29,982 |
| XareltoRivaroxaban | 17 | $19,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr | $275 | $538,244391 claims |
| MerckJanuvia, Janumet | $149 | $186,500142 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $121 | $106,79684 claims |
| PfizerEliquis | $59 | $92,15971 claims |
| AstraZenecaFarxiga, Symbicort | $88 | $78,88976 claims |
| AbbVieLinzess | $155 | $61,15864 claims |
| BayerKerendia | $75 | $57,57739 claims |
| Novo NordiskOzempic, Levemir | $221 | $32,61942 claims |
| NovartisEntresto | $28 | $32,08918 claims |
| GSKBreo Ellipta | $47 | $31,02654 claims |
| Johnson & JohnsonXarelto | $228 | $19,47917 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $9,61540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tolleson
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
- Corey AndersonMesa$21.5M
- Dena PetersenTucson$14.7M
- Gerald ShockeyMesa$12.3M
- Brock MerrittPhoenix$8.4M
- John McGettiganTucson$8.3M
- Neil ShethChandler$6.7M
- Joseph LilloScottsdale$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.